5.52
+0.06
(1.10%)
After Hours: 5.52
0.00
(0.00%)
May 20, 4:23PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 5.44 - 5.74 |
| 52 week | 2.30 - 6.85 |
| Open | 5.44 |
| Vol / Avg. | 459,076.00/311,024.00 |
| Mkt cap | 284.88M |
| P/E | - |
| Div/yield | - |
| EPS | -0.85 |
| Shares | 51.61M |
| Beta | 2.25 |
| Inst. own | 96% |
Events
Aug 5, 2013
Q2 2013 Sunesis Pharmaceuticals, Inc. Earnings Release
May 21, 2013
Sunesis Pharmaceuticals, Inc. at UBS Global Healthcare Conference
- 12:30PM EDT -
May 14, 2013
Sunesis Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
May 13, 2013
Q1 2013 Sunesis Pharmaceuticals, Inc. Earnings Release
May 9, 2013
Q1 2013 Sunesis Pharmaceuticals, Inc. Earnings Conference Call -
May 1, 2013
Sunesis Pharmaceuticals, Inc. at Needham Healthcare Conference
Mar 19, 2013
Sunesis Pharmaceuticals, Inc. at Roth Conference
Mar 15, 2013
Q4 2012 Sunesis Pharmaceuticals, Inc. Earnings Release
Mar 13, 2013
Q4 2012 Sunesis Pharmaceuticals, Inc. Earnings Conference Call -
Mar 5, 2013
Sunesis Pharmaceuticals, Inc. at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -584.41% | -1170.78% |
| Operating margin | -393.77% | -921.84% |
| EBITD margin | - | -921.02% |
| Return on average assets | -68.91% | -73.94% |
| Return on average equity | -713.94% | -219.88% |
| Employees | 25 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 400 395 Oyster Point Boulevard
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2663500 (Phone)
+1-650-2663501 (Fax)
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2663500 (Phone)
+1-650-2663501 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company�s VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company's Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.
Officers and directors
| Daniel N. Swisher Jr. | President, Chief Executive Officer, Director | |
| Eric H Bjerkholt | Chief Financial Officer, Executive Vice President - Corporate Development and Finance | |
| Adam R Craig MD,PhD | Executive Vice President - Development, Chief Medical Officer | |
| James W. Young Ph.D. | Non-Executive Independent Chairman of the Board | |
| Steven B Ketchum Ph.D. | Director | |
| Mathew K. Fust | Independent Director | |
| Edward Hurwitz | Independent Director | |
| Helen S. Kim | Independent Director |